Is ligustilide an anti-inflammatory and anti-aging phthalide compound?

In the fields of natural Chinese medicine standards, cardiovascular pharmacology, and neurodegenerative disease research, Ligustilide is a hallmark phthalate active ingredient in the volatile oils of Ligusticum striatum and Angelica sinensis. It utilizes the conjugated double-bond skeleton of the hydrogenated phthalate ring to achieve multi-pathway synergistic regulation. This substance possesses various activities, including blood-brain barrier penetration, antiplatelet aggregation, neuro-antioxidant activity, organ anti-inflammatory and anti-fibrotic activity, anticancer activity, and insecticidal activity. It can serve as a dedicated reference standard for the quality testing of Chinese medicinal materials, is a core reagent in in vitro cell experiments for cerebral ischemia, Alzheimer's disease, and atherosclerosis, and provides lead compound skeletons for the development of novel natural drugs for cardiovascular and cerebrovascular diseases. It is the powder raw material with the most complete in vivo pharmacological data among natural phthalate raw materials.

⚛️Natural lipophilic backbone with hydrogenated phthaloyl ring and alkenyl side chain

Ligustilide, chemically named 3-butenyl-4,5-dihydroisobenzofuranone, has the molecular formula C₁₂H₁₄O₂ and a molecular weight of 190.24 Da. Its core is a tetrahydrophthalide-based hydrogenated lactone ring, with an unsaturated butene side chain attached to position 3. The carbon-carbon double bond in this side chain forms two geometric isomers: Z-cis and E-trans. In natural plant extracts, Z-Ligustilide accounts for over 90% of the composition, exhibiting significantly superior bioactivity compared to the E-isomer. The oxygen atom in the hydrogenated lactone ring forms a conjugated electron structure with the carbonyl group, which, combined with the side chain double bond, constructs a delocalized electron system. This structure is fundamental for the molecule's ability to scavenge reactive oxygen species and penetrate the lipid layer of cell membranes.

 

The oxygen atom inside the lactone ring can form stable hydrogen bonds with various functional proteins within the cell, firmly attaching to the binding pocket of target proteins and significantly enhancing the molecule's affinity. The overall molecule lacks strongly ionized hydrophilic groups, belonging to a moderately lipid-soluble natural small molecule. It contains no chiral carbon atoms, relying solely on double bonds to produce two geometric configurations. The chemical synthesis process allows for the targeted enrichment of highly active Z-type components. After multi-stage molecular distillation, silica gel chromatography, and low-temperature recrystallization, the HPLC purity of the finished product can be stably maintained above 98%, effectively reducing the interference of isomer impurities on cell experimental data. The conjugated lactone structure inherently possesses excellent chemical stability; it will not easily oxidize or deteriorate when stored at room temperature in a light-proof, sealed container. Only prolonged exposure to strong light will cause a slight yellowing. Industrial storage utilizes light-proof aluminum foil bags to isolate the raw material from light, ensuring its stable activity.

 

In terms of physicochemical appearance, the crudely extracted Ligustilide is a pale yellow oily liquid with weak hygroscopicity and possesses a light herbal aroma characteristic of Ligusticum chuanxiong. The solubility is clearly differentiated; it is completely soluble in organic reagents, and DMSO is commonly used to prepare and store stock solutions in cell culture experiments. However, its solubility in pure water and phosphate buffer is very low; aqueous solutions are only suitable for immediate preparation, and fine yellow crystals will precipitate upon prolonged standing. For in vivo animal administration, it is often combined with medium-chain plant oils to aid dissolution and increase the drug concentration.

 

Industrial preparation includes two mature routes: natural plant extraction and total chemical synthesis. Natural extraction uses dried Ligusticum chuanxiong rhizome as raw material. Volatile oil components are collected by steam distillation, followed by molecular distillation to enrich phthalide mixtures. Low-temperature recrystallization and drying yield the powdered product. Chemical synthesis uses phthalimide and butenal as starting materials. Acidic catalytic cyclization constructs a hydrogenated phthalide core, and precise temperature control enriches Z-type alkenyl side chains. Multi-stage purification removes raw material residues and inefficient E-type isomers. The finished product meets standards for heavy metals, organic solvent residues, and endotoxins, making it suitable for various research scenarios such as cell incubation, in vitro tissue culture, and in vivo administration to small animals.

🧬Research reagents for multiple fields including cardiovascular and cerebrovascular diseases, neurological diseases, and quality control of traditional Chinese medicine

The most prevalent research application of this powder is in vitro cell and in vivo animal models for exploring neurodegenerative diseases. In experiments related to Alzheimer's disease, Parkinson's disease, and acute cerebral ischemia, researchers dissolved Ligustilide in DMSO and added it to the culture medium of dopamine neurons and hippocampal neurons to observe changes in β-amyloid protein deposition, the number of surviving dopamine neurons, the proportion of apoptotic cells, and mitochondrial activity, verifying its role in scavenging free radicals in the brain and inhibiting the aggregation of abnormal proteins. In models of cerebral ischemia-hypoxia injury, adding the powder dilution to treat damaged neurons downregulated the expression levels of ischemia-related genes, elucidating the complete mechanism by which ligustilide penetrates the blood-brain barrier to protect brain cells, and accumulating a large amount of basic data for the development of candidate natural drugs for stroke and Alzheimer's disease.

 

Pharmacological experiments on cerebrovascular dilation, antithrombosis, and cardioprotection are suitable for research on vascular smooth muscle cells and primary cardiomyocytes. This powder can inhibit platelet aggregation and relax smooth muscle in microvessels throughout the body. The research team conducted a rat thoracic aortic ring tension test, recording the amplitude of vascular dilation at different drug concentrations to further explore the intrinsic mechanism of calcium ion channel regulation. Adding this reagent to a cell model of myocardial ischemia-reperfusion injury reduced oxidative stress damage in cardiomyocytes, downregulated the expression of pro-apoptotic proteins in myocardium, alleviated the process of myocardial fibrosis, and simultaneously monitored changes in myocardial cell energy metabolism. This also improved the pharmacological database of natural lactone-based cardioprotective substances and supported the pharmacodynamic mechanism analysis of traditional Chinese medicine compound formulas containing Ligusticum chuanxiong and Angelica sinensis.

The investigation of anti-fibrotic mechanisms in the lungs and liver is a rapidly expanding application area in recent years. In vitro cell models of pulmonary fibrosis and liver fibrosis were both conducted using Ligustilide. After powder treatment, the epithelial-mesenchymal transition process in myofibroblasts was significantly inhibited, and collagen secretion was significantly reduced. Researchers simultaneously observed changes in the expression of fibrosis-related TGF-β pathway genes, establishing a complete experimental system for pathological intervention in organ fibrosis. This provides a natural positive control reagent for screening innovative anti-fibrosis drugs, compensating for the high toxicity and side effects of chemically synthesized fibrosis inhibitors.

 

The raw material's unique industrial application is as a quality testing standard for traditional Chinese medicine (TCM) materials. Ligustilide is a hallmark active substance in the volatile oils of umbelliferous herbs such as Ligusticum chuanxiong, Angelica sinensis, and Ligusticum striatum. High-purity Ligustilide is used as a liquid chromatography reference in domestic pharmacopoeias and enterprise internal control testing to accurately detect its content in TCM materials, processed TCM slices, and TCM extracts. This standardizes the quality grading of TCM materials, controls the content of effective components in TCM preparations, and ensures the stable and consistent quality of TCM products.

 

In addition, this powder is used in three auxiliary research scenarios: natural antibacterial activity, skin anti-oxidation, and metabolic regulation. In terms of antibacterial properties, it can inhibit the proliferation of Candida albicans and pathogenic bacteria on the skin surface, and can be used as a natural preservative active ingredient for formulation testing. In terms of skin, it can alleviate skin collagen loss caused by ultraviolet radiation by relying on its antioxidant effects, and develop transdermal repair preparations. In terms of metabolism, it can regulate lipid deposition in blood vessels and be used in intervention tests of hyperlipidemia and atherosclerosis cell models, continuously expanding the scientific research application boundaries of ligustilide powder.

🎯Multi-layered pathways including barrier penetration, anti-oxidation, anti-inflammation, and anti-fibrosis.

Ligustilide exerts its full physiological activity through a five-tiered, progressive mechanism: blood-brain barrier penetration, activation of the Nrf2 antioxidant pathway, blocking of the NF-κB inflammatory pathway, inhibition of the TGF-β fibrosis pathway, and regulation of mitochondrial apoptosis. Its natural lactone structure allows for the simultaneous regulation of multiple cellular signaling pathways, avoiding the blockage of any single physiological signal. It gently repairs various types of cellular damage, making it suitable for long-term cell incubation and continuous administration in small animals.

 

The first step of its action relies on its moderately lipid-soluble hydrogenated lactone backbone to penetrate the cell membrane and blood-brain barrier, achieving targeted accumulation in brain tissue. Its balanced lipid-water partition coefficient allows it to easily penetrate the phospholipid bilayer of the cell membrane. After oral or intraperitoneal administration, the molecules cross the endothelial cell gaps of the blood-brain barrier and accumulate in the cerebral cortex, hippocampus, and midbrain dopamine neurons. The drug concentration in brain tissue is significantly higher than in peripheral organs such as the liver and kidneys. It can directly reach the neurological damage target without additional carrier modification, greatly reducing the potential stimulation associated with systemic administration.

 

The second step activates the cellular Nrf2 endogenous antioxidant pathway, clearing excess reactive oxygen species (ROS) within the cell. The conjugated lactone ring of the molecule carries delocalized electrons, enabling it to directly capture oxidizing substances such as hydroxyl radicals, superoxide anions, and hydrogen peroxide, blocking the free radical chain reaction and reducing oxidative damage to cellular DNA and mitochondrial lipids. Simultaneously, the molecule enters the cell and binds to the Keap1 protein, releasing Keap1's binding restriction on the Nrf2 transcription factor. The Nrf2 protein then translocates to the nucleus, initiating the transcription of downstream endogenous antioxidant proteins such as SOD and glutathione, strengthening the cell's own antioxidant protection capacity. This dual antioxidant mechanism alleviates oxidative stress damage caused by cerebral ischemia and neuroaging.

 

The third step inhibits the NF-κB pro-inflammatory signaling pathway, downregulating the release of various pro-inflammatory factors in the body. After cell injury, the NF-κB protein translocates into the nucleus, initiating the transcription of inflammation-related genes and releasing pro-inflammatory factors such as TNF-α, IL-6, and IL-1β, continuously exacerbating tissue inflammation. Ligustilide can block the nuclear translocation of NF-κB protein, inhibiting the transcription of inflammatory genes at the source, reducing the secretion of various pro-inflammatory factors, and alleviating neuroinflammation in the brain, myocardium, and chronic lung inflammation. Its antioxidant and anti-inflammatory effects work synergistically to eliminate the persistent low-grade inflammation induced by oxidative stress.

 

The fourth step blocks the TGF-β/Smad fibrosis signaling pathway, inhibiting myofibroblast proliferation and abnormal collagen deposition. The core of organ fibrosis pathology is the overactivation of TGF-β signaling, which induces normal somatic cells to transform into myofibroblasts, leading to the accumulation of large amounts of collagen and the formation of fibrotic scars. This powder can bind to TGF-β receptors on the cell membrane surface, inhibiting the phosphorylation of downstream Smad protein, blocking the downward transmission of fibrosis signals, reducing the proliferation rate of myofibroblasts, downregulating the expression of type I and type III collagen genes, preventing abnormal collagen accumulation in organ tissues, and reversing early fibrotic cell lesions.

The fifth step regulates the mitochondrial apoptosis pathway, reducing excessive programmed apoptosis in damaged cells. Oxidation and inflammation can disrupt mitochondrial membrane integrity, releasing cytochrome C and initiating apoptosis. Ligustilide can stabilize mitochondrial membrane potential, maintain mitochondrial membrane structural integrity, downregulate pro-apoptotic Bax protein expression, upregulate anti-apoptotic Bcl-2 protein levels, inhibit the release of cytochrome C, block excessive apoptosis of damaged neurons and cardiomyocytes, preserve normal somatic cell physiological activity, and complete the protection and repair of damaged tissue cells.

🔭Formulation Improvement and Anti-aging Applications

The core research and development focus is on the chemical modification of the phthalide skeleton to synthesize highly active novel derivatives. Natural ligustilide exhibits poor water solubility, leaving significant room for improvement in blood dissolution efficiency. The research team has conducted chemical modifications targeting two functional sites: the carbonyl group of the lactone ring and the butenyl side chain. This involves introducing hydrophilic hydroxyl groups, amino acid fragments, and polyethylene glycol branches to synthesize a series of ligustilide derivatives. Some of these modified products show more than double the cell penetration efficiency, significantly reducing the dosage required for the same neuroprotective effect and minimizing the slight cytotoxicity associated with DMSO organic solvent dissolution. Simultaneously, optimizing the proportion of Z-type active isomers further enhances target binding affinity, providing a complete chemical library for next-generation, highly effective natural phthalide drug candidates.

 

The development of water-soluble salt-type and nanocarrier delivery formulations addresses the dissolution limitation and is suitable for in vivo drug administration experiments in small animals. Free ligustilide has extremely low water solubility, requiring large amounts of organic solvents for intravenous and intraperitoneal administration, which can easily induce peritoneal irritation. The industry has developed lactate-modified products, significantly improving molecular water solubility and allowing for direct dilution with physiological saline for drug administration. Simultaneously developing liposome nanospheres and phospholipid complex carrier formulations, the nanocarriers encapsulate powder molecules, preventing precipitation in animal body fluids, prolonging the in vivo blood circulation half-life, and increasing drug accumulation in brain tissue and lung organs. These formulations are suitable for administration in Parkinson's disease mouse models and animal intervention experiments for pulmonary fibrosis, expanding the application boundaries of in vivo drug delivery.

 

The disease indications continue to expand, exploring more interventional potential of natural phthalide. Traditional applications focus on three main areas: cerebral ischemia, Alzheimer's disease, and organ fibrosis. Currently, the research team is expanding to four major pathological models: Parkinson's disease, age-related myocardial degeneration, diabetic hyperglycemic oxidative damage, and skin photoaging, verifying the protective effects of this powder on nerve, myocardial, and skin cells under different pathological conditions. In the metabolic field, animal experiments on hyperlipidemia are being conducted to investigate its role in assisting in the regulation of blood lipids and inhibiting arterial plaque formation, targeting the mechanism of vascular lipid deposition. In the skin field, transdermal gel formulations are being developed using antioxidant and anti-inflammatory properties to alleviate UV-induced collagen loss in the skin, continuously expanding the pathological research areas covered by Ligustilide.

 

The development of synergistic formulations combining multiple natural active ingredients enhances overall therapeutic effects. The single pathway of action of Ligustilide has limitations; therefore, the industry combines it with other natural active substances such as tetramethylpyrazine, resveratrol, curcumin, and 3-butylidenephthalide to achieve synergistic effects through the different pathways of action of these components. For example, combining it with tetramethylpyrazine strengthens microvascular dilation and antithrombotic effects; combining it with resveratrol enhances antioxidant and anti-inflammatory activities; and combining it with 3-butylidenephthalide optimizes brain nerve repair effects. This combination significantly reduces the dosage of single ingredients while simultaneously addressing multiple needs such as neuroprotection, vasodilation, and antioxidation. It is suitable for multi-symptom cardiocerebrovascular injury cell model experiments and also provides formulation ideas for the development of functional oral dietary products.

 

The standardization system for the control of traditional Chinese medicine materials continues to improve. For the specifications of Ligustilide chromatographic standards, research institutions have improved a complete set of liquid chromatography testing procedures, distinguishing between cell research grade and traditional Chinese medicine control grade, standardizing purity, organic solvent residue, and microbial limits, and providing complete COA test reports. Simultaneously conduct in vivo metabolomics studies of raw materials to fully track the entire process of absorption, distribution, metabolism, and excretion after oral administration of the molecules, improve the in vitro cytotoxicity and short-term in vivo toxicology data of ligustilide, and build a complete database of safe use to support the stable progress of traditional Chinese medicine testing and new drug screening projects.

Conclusion

Ligustilide, a signature natural phthalide active ingredient derived from Ligusticum chuanxiong and Angelica sinensis, is a 98% high-purity, light yellow powder with stable physicochemical properties. Utilizing a natural chemical framework of hydrogenated lactone rings and unsaturated alkenyl side chains, it can penetrate the blood-brain barrier, simultaneously activating the Nrf2 antioxidant pathway, inhibiting the NF-κB inflammatory pathway, blocking the TGF-β fibrosis pathway, stabilizing mitochondria and reducing apoptosis. It also possesses multiple activities including neuroprotection, vasodilation, antiplatelet aggregation, anti-organ fibrosis, and natural antibacterial activity. This powder covers diverse research scenarios, including cell experiments for neurodegenerative diseases, cardiovascular pharmacology research, in vitro models of organ fibrosis, and liquid chromatography standards for traditional Chinese medicine. Its natural multi-target mechanism of action avoids pathway compensatory interference from single chemical inhibitors, making it a highly versatile standard reagent among natural lactone research raw materials.

 

To learn more about our Ligustilide or to request a quote, please contact our knowledgeable sales team at allen@faithfulbio.com.

References

1. Su, C. Y., et al. (2014). Ligustilide ameliorates neuronal damage via Nrf2/ARE antioxidant pathway in cerebral ischemia models. Journal of Ethnopharmacology, 155(2), 921-929.
2. Chao, W. W., et al. (2018). Antiplatelet and vasodilatory activities of Z-ligustilide isolated from Angelica sinensis. Phytomedicine, 45, 116-122.
3. Li, Y., et al. (2021). Ligustilide suppresses pulmonary fibrosis through inhibiting TGF-β/Smad signal transduction. International Journal of Molecular Sciences, 22(18), 10045.
4. Wang, X., et al. (2023). Liposomal ligustilide improves brain targeting efficiency and anti-Alzheimer effects in APP/PS1 mice. Journal of Controlled Release, 361, 743-756.
5. Chen, L., et al. (2022). Structure-activity relationship of ligustilide derivatives on neuroprotective activity. Journal of Medicinal Chemistry Research, 31(7), 1012-1024.
6. Zhang, Q., et al. (2020). Ligustilide as official reference standard for quality control of Ligusticum chuanxiong. Chinese Herbal Medicines, 12(3), 278-284.
7. Phytochem R&D Center. (2026). Ligustilide 98% Powder Product Specification & Application Guide. Internal Technical Document.